Recursion Pharmaceuticals’ (RXRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX) in a research report released on Monday morning,Benzinga reports. Needham & Company LLC currently has a $8.00 price objective on the stock.

A number of other research firms have also recently weighed in on RXRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a report on Friday, October 16th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 17th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.18.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $3.64 on Monday. The company has a market cap of $1.95 billion, a P/E ratio of -3.50 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The business’s 50 day moving average price is $3.65 and its 200-day moving average price is $3.43. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $6.50.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter in the previous year, the company posted ($0.41) EPS. Sell-side analysts predict that Recursion Pharmaceuticals will post -0.93 earnings per share for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total transaction of $125,000.00. Following the sale, the director owned 162,156 shares of the company’s stock, valued at approximately $810,780. This trade represents a 13.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the transaction, the director owned 6,108,287 shares in the company, valued at $29,564,109.08. This represents a 0.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 157,408 shares of company stock valued at $643,576 over the last 90 days. Corporate insiders own 6.65% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. MCF Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth $27,000. Fund Advisors of America Inc FL bought a new position in Recursion Pharmaceuticals in the second quarter worth about $45,000. Integral Investment Advisors Inc. bought a new position in Recursion Pharmaceuticals in the first quarter worth about $39,000. MQS Management LLC purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at about $41,000. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock valued at $47,000 after buying an additional 5,156 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.